# Investigator-Initiated Study of Imipramine Hydrochloride and Lomustine in Recurrent Glioblastoma

> **NCT04863950** · PHASE2 · RECRUITING · sponsor: **The University of Texas Health Science Center at San Antonio** · enrollment: 25 (estimated)

## Conditions studied

- Glioblastoma

## Interventions

- **DRUG:** Lomustine
- **DRUG:** Imipramine Hydrochloride

## Key facts

- **NCT ID:** NCT04863950
- **Lead sponsor:** The University of Texas Health Science Center at San Antonio
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-05-25
- **Primary completion:** 2026-08
- **Final completion:** 2026-11
- **Target enrollment:** 25 (ESTIMATED)
- **Last updated:** 2025-08-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04863950

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04863950, "Investigator-Initiated Study of Imipramine Hydrochloride and Lomustine in Recurrent Glioblastoma". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04863950. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*